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Aim: To determine whether a liver tumor burden ≤25% and well-preserved liver function (albumin-
bilirubin grade 1) are appropriate criteria for identifying patients with unresectable hepatocellular carci-
noma who may benefit from selective internal radiation therapy (SIRT) using 90yttrium resin microspheres
versus sorafenib. Patients & methods: Post-hoc analysis of patients in the intention-to-treat population of
the SARAH trial (SIRT vs sorafenib) with ≤25% tumor burden and albumin-bilirubin grade 1. Primary end
point: overall survival. Results: Median overall survival was 21.9 months (95% CI: 15.2–32.5, n = 37) with
SIRT and 17.0 months (11.6–20.8, n = 48) with sorafenib (hazard ratios: 0.73 [95% CI: 0.44–1.21; p = 0.22]).
Conclusion: A combination of good liver function and low tumor burden may be relevant for selection of
hepatocellular carcinoma patients for SIRT.
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The incidence of hepatocellular carcinoma (HCC) is increasing worldwide, and many patients have intermediate-
or advanced-stage HCC at presentation when potentially curative treatments, such as surgical resection or tumor
ablation, are no longer practicable. For patients with advanced-stage disease treatment is limited to systemic
therapies. First-line treatment is based on the tyrosine kinase inhibitors sorafenib and lenvatinib [1–3]. Sorafenib has
been used as first-line treatment for advanced HCC following the publication of the Phase III SHARP trial, which
showed an overall survival (OS) benefit of sorafenib versus placebo [1,2]. However, adverse events (AE) associated
with sorafenib treatment are frequent and can necessitate discontinuation of treatment and dose reduction [1,2,4].
Lenvatinib is noninferior to sorafenib in the treatment of HCC, but has no advantage in terms of tolerability [3].
There is, therefore, an unmet need for effective and well-tolerated treatments in advanced HCC. Selective internal
radiation therapy (SIRT) may provide an additional alternative for patients with unresectable HCC without extra-
hepatic metastases for whom curative treatments or transarterial chemoembolization (TACE) are not appropriate
options, or who have failed on these treatments.
Two multicenter randomized controlled trials (RCT) in Europe (SARAH) [5] and Asia Pacific (SIRveNIB) [6]
compared SIRT using 90yttrium (90Y) resin microspheres (SIR-Spheres R©; Sirtex, Sydney, Australia) and sorafenib
400 mg twice daily in patients with unresectable HCC not eligible for TACE. These RCTs did not show a
statistically significant benefit of SIRT over sorafenib in terms of OS, but did show some benefits of SIRT in other
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measures such as tumor response rate, disease progression in the liver as first event, and frequency and severity of
treatment-related AEs [5,6].
The SARAH trial, which was initiated in 2009, recruited patients with HCC who were ineligible for curative
treatment or had failure after up to two rounds of TACE. The recruited population had a broad range of baseline
characteristics, including factors that confer a poor prognosis (such as a compromised liver function [Child-Pugh
up to B7, bilirubin up to 50 mmol/l] and/or a severe burden of disease [tumor burden >25% of the liver, complete
occlusion of the main portal vein]). These selection criteria may have resulted in the recruitment of patients who
were poor candidates for SIRT [7,8].
While the current European Association for the Study of the Liver (EASL) and European Society for Medical
Oncology (ESMO) guidelines highlight the importance of liver function and tumor burden when selecting
treatments for patients with HCC, there is no consensus on the criteria for stratifying patients to receive either
locoregional therapy or systemic treatment [9,10].
This post hoc subgroup analysis of the SARAH trial was, therefore, conducted to determine whether a tumor
burden ≤25% of the total liver volume and well-preserved liver function defined as an albumin-bilrubin (ALBI)
grade of 1 may act as stratification criteria to assign patients to receive either SIRT using 90Y resin microspheres or
sorafenib 400 mg twice daily.
Materials & methods
SARAH was a multicenter RCT performed at 25 centers in France (ClinicalTrials.gov, number NCT01482442) [5].
SARAH was performed in accordance with the Declaration of Helsinki, approved by an ethics committee, and
complied with the provisions of the International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use Guidelines for Good Clinical Practice. All patients provided written informed
consent [5].
The primary objective of this analysis was to explore OS in patients with tumor burden ≤25% and an ALBI
grade of 1 in the intention-to-treat (ITT) population of the SARAH trial to inform patient selection for SIRT
using 90Y resin microspheres in unresectable HCC, either locally advanced, recurrent or refractory to TACE.
Patients
The inclusion criteria for SARAH have been described previously [5,11]. The main criteria were, a diagnosis of HCC,
either locally advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage C) without extrahepatic metastases,
recurrent HCC after previous surgical or thermoablative therapy with curative intent and which is ineligible for
resection, transplantation or ablation, or HCC after failing up to two rounds of TACE [11].
This analysis was conducted on patients from the ITT population in the SARAH trial who had a tumor burden
≤25% (i.e., tumoral replacement of up to 25% of the liver volume) and an ALBI grade of 1 at baseline [5]. The
ALBI grade is calculated from serum albumin and bilirubin levels based on the formula (log10 bilirubin × 0.66)
+ (albumin × -0.085) and categorized into three different grades: Grade 3 (>-1.39), Grade 2 (>-2.60 to ≤-1.39)
and Grade 1 (≤-2.60), with Grade 1 reflecting better preserved liver function than Grade 2 or 3 [12,13].
Study treatment
Eligible patients were randomly assigned (1:1) to receive either SIRT or sorafenib [5]. Oral treatment with sorafenib
started at 400 mg twice daily in the week following randomization. Treatment discontinuation or dose reduction
were described in the main publication [5]. Patients assigned to SIRT underwent angiography of the hepatic artery
and protective coiling of extrahepatic branches as required. Technetium-99m macroaggregated albumin (99mTc-
MAA) was injected into the hepatic artery using the same catheter position chosen for the scheduled SIRT session
for the liver perfusion scan. Dose activity was calculated according to the modified body surface area model [14] by
the center performing SIRT [5].
Patients underwent SIRT 1 or 2 weeks after hepatic angiography using 90Y-labeled resin microspheres (SIR-
Spheres; Sirtex). A lobar, sectoral or segmental approach was utilized according to tumor size and location. For
bilobar tumors, the first treatment was performed in the hemiliver with the greatest tumor burden, with treatment
of the contralateral hemiliver scheduled 30–60 days later. SIRT could be repeated if the tumor progressed [5].
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Outcome measures
The primary end point of interest was OS defined as the time from the date of randomization to death from any
cause, or censored at the date of the last follow-up if the patient was alive.
Secondary end points were progression-free survival (PFS) defined as the time from randomization to disease
progression, and the number of patients who underwent subsequent treatment with curative intent (i.e., surgical
resection, liver transplantation, tumor ablation).
Statistical analysis
Analyses were performed in subgroups of the ITT population. OS and PFS were estimated using Kaplan–Meier
curves. A Cox model was used to calculate hazard ratios (HR) and their two-sided 95% CIs. A per-protocol analysis
was not deemed necessary as the 92% of the patients who had been randomized to SIRT received the allocated
treatment. Subgroup effects were tested using a Cox proportional hazards model incorporating an interaction term.
A treatment effect favoring SIRT over sorafenib was suggested if HR <1.
Results
Between December 2011 and March 2015, 467 patients were recruited to the SARAH trial [5], of these, eight
patients subsequently withdrew consent, and 459 were included in the ITT population. It was not possible to
estimate the ALBI grade for 15 patients (four in the sorafenib arm and 11 in the SIRT arm), and of these, ten had a
tumor burden ≤25% and were excluded as they could not be assigned to the analysis group, and five had a tumor
burden more than 25% and were included as they could be assigned to the population with ALBI grade >1 and/or
tumor burden more than 25%. The final study population comprised 449 patients. In this study population, 85
patients – 37 (16%) patients in the SIRT arm and 48 (22%) in the sorafenib arm – had a tumor burden ≤25%
and an ALBI grade of 1 and were included in this analysis.
The number of patients in each subgroup and their baseline characteristics are reported in Table 1. Baseline
characteristics were well-balanced between the treatment arms with the exception of: ECOG performance status
1, which was more frequent in the SIRT arm; and bilobar disease, which was more frequent in the SIRT arm,
however, neither difference was statistically significant (Table 1).
Of the 37 patients in the subgroup with a tumor burden ≤25% and an ALBI grade 1 randomized to receive
SIRT, 34 (92%) received the treatment: all 48 patients randomized to sorafenib received the allocated treatment. In
contrast, in the SARAH trial overall 53/237 (22%) randomized to SIRT did not receive their allocated treatment;
216/222 (97%) of patients randomized to sorafenib received their allocated treatment [5].
Median OS in the SIRT arm was 21.9 months (95% CI: 15.2–32.5) and 17.0 months (95% CI: 11.6–20.8)
in the sorafenib arm (HR: 0.73; 95% CI: 0.44–1.21; p = 0.22; Figure 1). The interaction effect estimate from
the Cox regression was 0.609 (95% CI: 0.344–1.079; p = 0.089) indicating that there was a trend favoring SIRT
over sorafenib in this subgroup, but statistical significance was not achieved. The effect of tumor burden and ALBI
grade on the relative effectiveness of SIRT and sorafenib was also apparent when comparing with outcomes for
patients with an ALBI grade >1 and/or a tumor burden more than 25% (Supplementary Table 1). Median OS for
these patients, who were not part of the target subgroup, was 6.5 months (95% CI: 5.7–8.3) in the SIRT arm and
9.5 months (95% CI: 7.1–10.3) in the sorafenib arm (Supplementary Figure 1).
A similar benefit of SIRT was observed in PFS: median PFS in the SIRT arm was 6.7 months (95% CI: 3.9–9.5)
and 3.7 months (95% CI: 3.2–6.0) in the sorafenib arm (HR: 0.65; 95% CI: 0.41–1.02; p = 0.06; Figure 2), but
statistical significance was not achieved. Median PFS for patients with an ALBI grade >1 and/or a tumor burden
more than 25% was similar in the two groups; 3.9 months (95% CI: 3.7–4.5) in the SIRT arm and 3.8 months
(95% CI: 3.3–5.6) in the sorafenib arm (Supplementary Figure 2).
A higher proportion of patients in the SIRT arm of the good liver function/low tumor burden subgroup
subsequently received curative treatment than in the sorafenib arm: 14% (5/37) versus 2.1% (1/48; Table 2).
Patients received their subsequent curative therapy after a mean 15.8 (SD: 8.98 months; median: 10 months,
range: 6–34 months) months after randomization and all were alive at a median follow-up of 25.0 months (range:
16.0–32.3). In the SARAH trial overall, 5.1% of patients who received SIRT subsequently received potentially
curative treatment: all but one were alive at a median follow-up of 27.9 months [5,15]. In the sorafenib group, 1.4%
of patients received potentially curative treatments [5].
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Table 1. Baseline characteristics of patients with ≤25% tumor burden and albumin-bilirubin grade 1.
Baseline characteristic SIRT (n = 37) Sorafenib (n = 48) p-value
Age (years)
≥65 16 (43) 23 (48) 0.83
65 21 (57) 25 (52)
ECOG performance status
0 22 (62) 38 (79) 0.14
1 15 (38) 10 (21)
2 0 0
BCLC stage
A 1 (3) 3 (6) 0.62
B 16 (43) 17 (35)
C 20 (54) 28 (58)
Number of tumor nodules (multifocal vs single nodule)
Multiple 21 (57) 32 (67) 0.48
Single 16 (43) 16 (33)
Number of tumor nodules
4 34 (92) 44 (92) 1.00
≥4 3 (8) 4 (8)
Macroscopic vascular invasion
No 17 (46) 23 (48) 1.00
Yes 20 (54) 25 (52)
Child-Pugh grade
A 35 (95) 47 (98) 0.82
B 2 (5) 1 (2)
Previous TACE
No 18 (49) 27 (56) 0.63
Yes 19 (51) 21 (44)
Occlusion of main portal vein
Absent 33 (89) 43 (90) 1.00
Present 4 (11) 5 (10)
Liver involvement
Bilobar 9 (24) 7 (15) 0.39
Unilobar 28 (76) 41 (85)
Data is represented as n (%).
BCLC: Barcelona clinic liver cancer; ECOG: Eastern cooperative oncology group; SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.
Table 2. Subsequent potentially curative treatment in patients with ≤25% tumor burden and albumin-bilirubin grade 1.
Treatment Patient’s status EOS Follow-up (months) Tumor burden at
baseline (%)
Potentially curative treatment received
Radiofrequency
ablation
Surgery Transplant
SIRT Alive 25 4 No No Yes
Alive 20 5 Yes No No
Alive 35 10 No No Yes
Alive 33 6 No Yes No
Alive 22 20 Yes No No
Sorafenib Dead 22 2 Yes No No
EOS: End of study; SIRT: Selective internal radiation therapy.
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Figure 1. Kaplan-Meier plot of overall survival for selective internal radiation therapy versus sorafenib in patients with ≤25% tumor
burden and albumin-bilirubin grade 1 in the SARAH trial.
SIRT: Selective internal radiation therapy.
Safety
Among patients with an ALBI grade 1 and a tumor burden ≤25%, 24/37 (65%) patients in the SIRT arm versus
47/48 (98%) patients in the sorafenib arm experienced at least one treatment-related AE (p = 0.0002). A statistically
significant reduction in the incidence of grade ≥3 AEs was also observed in the SIRT arm compared with the
sorafenib arm, with respectively 9/37 (24%) versus 30/48 (63%) reporting at least one grade ≥3 AE (p = 0.001;
Table 3). Most grade ≥3 AEs were reported more frequently in the sorafenib arm than in the SIRT arm (Table 3).
AEs known to be associated with sorafenib treatment, which included grade ≥3 hand–foot skin reaction, were
reported in 4/48 (8.3%) of patients in the sorafenib arm and none in the SIRT arm. Diarrhea was reported in
7/48 (15%) of patients in the sorafenib arm and none in the SIRT arm.
Discussion
This analysis of data from the SARAH trial suggests that a low tumor burden (≤25%) in combination with
good liver function (ALBI grade of 1) may be useful in identifying HCC patients for whom SIRT with 90Y resin
microspheres is associated with better OS than sorafenib. However, the HR for the OS did not reach statistical
significance, possibly due to the small size of the subgroup.
In this subgroup analysis, median OS was longer in both the SIRT and sorafenib arms than in the primary
analysis of the ITT population in the SARAH trial where median OS was 8.0 and 9.9 months, respectively [5].
Likewise in this subgroup, median PFS in the SIRT arm was longer than in the primary analysis of the ITT
population in the SARAH trial, 6.7 and 4.1 months, respectively, while PFS in the sorafenib arm was 3.7 months
both in this subgroup analysis and in the primary analysis of the SARAH study [5].
ECOG performance status 1 and bilobar disease were more frequent in the SIRT arm of this subgroup. Both of
these characteristics are negative prognostic criteria. ECOG performance status of 1 is known to be a predictor of
poor survival after both SIRT with 90Y resin microspheres and sorafenib treatment [16,17]. Bilobar liver involvement
is a predictor of poor survival after SIRT [17]. Consequently, baseline characteristics in this subgroup were not
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Figure 2. Kaplan-Meier plot of progression-free survival for selective internal radiation therapy versus sorafenib in patients with ≤25%
tumor burden and albumin-bilirubin grade 1 in the SARAH trial.
SIRT: Selective internal radiation therapy.
expected to favor SIRT and could result in conservative estimates of OS and PFS compared with sorafenib.
Furthermore, a proportion of patients in the current analysis had previously failed TACE. The impact that previous
TACE failure may have on outcomes with SIRT versus sorafenib are not known, and further research may also
elucidate this as a potential criterion for patient selection.
The current ESMO and EASL guidelines acknowledge that there is no consensus on tumor volume and liver
function criteria that may help in treatment selection for patients with advanced HCC, and consequently any
chosen cutoffs are not fully evidence-based. The rationale for choosing a subgroup from the SARAH trial with
≤25% of the total liver volume was that patients with a lower tumor volume may be most likely to benefit from
SIRT due to improved targeting of the liver tumors. This cutoff was predefined in the SARAH trial, and has been
used for SIRT patient selection in indications other than HCC [18–25]. In addition, a cutoff of tumor burden ≤25%
is used in some countries as a criteria for using or reimbursing SIRT in other indications [26,27]. Patients with a lower
tumor burden may have received a higher dose of radiation to the tumor in the SARAH trial, especially with the
use of the body surface area model for activity calculation: a tumor-absorbed dose ≥100 Gy has been identified as a
predictor of prolonged OS following SIRT using 90Y resin microspheres [22]. It is of course true that the selection of
patients with a good prognosis based on tumor burden and liver functional reserve is also likely to improve outcomes
of systemic therapy with sorafenib (as is observed in this analysis when the OS in this subgroup is compared with
the SARAH population overall). However, we hypothesized that the relative benefits with SIRT over sorafenib
may be greater due to the differences in mode of action between SIRT and sorafenib, and their relationship to the
physiological disease characteristics of HCC. Observational studies have reported a correlation between number
of tumors, their maximum size and their dissemination in the liver with OS following SIRT [17,28,29], whereas the
number of tumors or their maximum size were not found to be treatment effect modifiers in Phase III trials of
sorafenib versus placebo [30].
The relationship between good functional reserve of the liver and reduced toxicity of SIRT to normal liver
parenchyma is well-documented [24]. Sorafenib has also been shown to be less effective in patients with impaired
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Table 3. Patients experiencing a grade ≥3 adverse event in the population with ≤25% tumor burden and
albumin-bilirubin grade 1.
Adverse event Patients experiencing treatment-related adverse events
SIRT (n = 37) Sorafenib (n = 48) p-value
Patients with any adverse event (any grade) 24 (64.9) 47 (97.9) 0.0002
Grade 3–4, adverse events:
– Patients with any Grade 3–4 adverse event 9 (24.3) 30 (62.5) 0.001
– Abdominal pain 1 (2.7) [1] 3 (6.3) [3] 0.803
– Anorexia 0 3 (6.3) [3] 0.339
– Cardiac failure, congestive 0 2 (4.2) [2] 0.593
– Diarrhea 0 7 (14.6) [9] 0.043
– Dry skin 0 2 (4.2) [2] 0.593
– Fatigue 1 (2.7) [1] 7 (14.6) [7] 0.137
– Gastrointestinal bleeding 1 (2.7) [1] 0 0.896
– Gastrointestinal ulceration 1 (2.7) [2] 0 0.896
– Hematological biological abnormalities 1 (2.7) [1] 3 (6.3) [10] 0.803
– Hemorrhage (nongastrointestinal) 0 2 (4.2) [2] 0.593
– Hand–foot skin reaction 0 4 (8.3) [5] 0.200
– Hyperbilirubinemia 0 1 (2.1) [1] 1.000
– Infection 0 1 (2.1) [3] 1.000
– Liver dysfunction 0 3 (6.3) [3] 0.339
– Nausea or vomiting 0 1 (2.1) [1] 1.000
– Other dermatological events 0 1 (2.1) [1] 1.000
– Other increased liver values 1 (2.7) [1] 1 (2.1) [1] 1.000
– Renal dysfunction (increased creatinine) 1 (2.7) [1] 1 (2.1) [1] 1.000
Data represented as n (%) [number of events].
liver function (Child-Pugh B) [31,32]. As ALBI grade provides an objective estimate of hepatic functional reserve [33],
we used the cutoff of ALBI grade 1 as a definition of well-preserved liver function. The ALBI grade is recognized
as a valid criterion for stratification of patients in prognostic groups of liver function within the Child-Pugh
A class [9,10,34], especially for patients with HCC receiving locoregional therapy [17,28,29,35] as ALBI considered
a better estimator of the liver functional reserve than Child-Pugh [10]. It was hypothesized that patients with
well-preserved liver function may be most likely to benefit from SIRT, because baseline serum albumin and
bilirubin have previously been identified as predictors of survival and toxicity outcomes of SIRT using 90Y resin
microspheres [12,13,17,24,28,29,34–37].
Outcomes of this analysis support the concept that the selection of patients with an ALBI grade 1 and a tumor
burden ≤25% is more influential on the outcomes of SIRT than it is for sorafenib. This is most apparent when
comparing PFS outcomes for the target subgroup versus the rest of the ITT population (i.e., ALBI grade >1 and/or
tumor burden >25%): in the SIRT arm, median PFS was 6.7 months in the subgroup in contrast to 3.9 months in
the rest of the ITT population; in the sorafenib arm, median PFS was 3.7 months in the subgroup and 3.8 months
in the rest of the ITT population.
A proportion of patients who receive SIRT for HCC that is unresectable at presentation may be downstaged, in
other words, may have a significant tumor response following therapy to become eligible for potentially curative
treatments [10,24]. In this subgroup analysis, a markedly higher proportion of patients who received SIRT were
downstaged to receive curative treatment than those treated with sorafenib. Patients are expected to have longer-
term survival after curative treatment [38,39], with a recent study showing higher OS for patients downstaged
following SIRT and even higher for those who received subsequent curative treatment [40]. However, due to the
censoring of the data in the SARAH trial, the survival benefits of downstaging to curative treatment following
SIRT, compared with sorafenib, may not have been observed in survival analyses in the trial.
AEs associated with sorafenib are frequent and may lead to the discontinuation of treatment [1,2,4]. In this
subgroup analysis, the incidence of any treatment-related AEs and grade ≥3 AEs was lower in the SIRT arm than
in the sorafenib arm, and the safety benefit of SIRT over sorafenib in this subgroup was greater than in the overall
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ITT population. Furthermore, AEs known to have an adverse effect on patients’ quality of life, such as grade ≥3
hand–foot skin reactions and diarrhea, predominantly occurred among patients who received sorafenib.
There are limitations to this analysis. Low tumor burden (≤25%) and good liver function was not a prespecified
subgroup in the SARAH trial. The ALBI score was not reported in the SARAH trial, but serum albumin and
bilirubin level data were collected. There are other potential prognostic factors for the stratification of HCC
patients to SIRT or systemic treatment. Adding other factors, such as BCLC stage or presence of macroscopic
vascular invasion, to the analysis may have resulted in a numerically larger benefit of SIRT versus sorafenib,
and thus may have given further guidance on patient selection, but would have further reduced the sample sizes
and prevented meaningful interpretation. Furthermore, univariate analyses of OS stratified by BCLC stage or
macroscopic vascular invasion did not demonstrate a benefit of SIRT using 90Y resin microspheres in the ITT and
per protocol populations of the SARAH trial [5].
A pooled analysis of data from both the SARAH and SIRveNIB studies, to increase the number of patients
available for analysis, may have provided strength to the findings, but this was not feasible. The SIRveNIB study
employed a different tumor burden cutoff and individual values of tumor burden were not available for the sorafenib
arm. Furthermore, baseline characteristics, risk factors for HCC and patient recruitment in the SIRveNIB trial
differed from those in SARAH, with the distribution of risk factors for HCC in SIRveNIB reflecting those in
Asia-Pacific population rather than a western population [5,6,10,41]. Hence, we focused this analysis on data from
the SARAH trial.
Conclusion
This analysis of the SARAH data supports the proposition that the combination of good liver function (ALBI
grade 1) and low tumor burden (≤25%) may be relevant in the selection of patients with locally advanced HCC
for SIRT with 90Y resin microspheres. This hypothesis warrants further research.
Summary points
• SARAH, a multicenter randomized controlled trial comparing selective internal radiation therapy (SIRT) using
90yttrium (90Y) resin microspheres and sorafenib 400 mg twice daily in patients with unresectable hepatocellular
carcinoma (HCC) not eligible for transarterial chemoembolization did not show a statistically significant benefit
of SIRT over sorafenib in terms of overall survival.
• SARAH showed some benefits of SIRT in other measures such as tumor response rate, and frequency and severity
of treatment-related adverse events (AEs).
• In SARAH, the recruited population had a broad range of baseline characteristics, including factors that confer a
poor prognosis (e.g., compromised liver function and/or a severe tumor burden [>25% of the liver]) that may
have led to the enrollment of patients who were poor candidates for SIRT.
• This post-hoc subgroup analysis of SARAH aimed to determine whether a liver tumor burden ≤25% and
well-preserved liver function (albumin-bilrubin grade 1) are appropriate criteria for identifying patients with
advanced HCC who may benefit from SIRT using 90Y resin microspheres versus sorafenib.
• There was a trend for improved median overall survival in the SIRT arm (21.9 months; 95% CI: 15.2–32.5, n = 37)
compared with the sorafenib arm (17.0 months; 95% CI: 11.6–20.8, n = 48; hazard ratio: 0.73; 95% CI:
0.44–1.21; p = 0.22).
• Median progression-free survival was longer in the SIRT arm (6.7 months; 95% CI: 3.9–9.5) and than in the
sorafenib arm (3.7 months; 95% CI: 3.2–9.5; hazard ratios: 0.65; 95% CI: 0.41–1.02; p = 0.06).
• Incidence of any treatment-related AEs and grade ≥3 AEs was lower in the SIRT arm than in the sorafenib arm, in
this analysis.
• This analysis of SARAH data supports the proposition that the combination of good liver function
(albumin-bilrubin grade 1) and low tumor burden (≤25%) may be relevant in the selection of patients with
locally advanced HCC for SIRT with 90Y resin microspheres.
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